Abstract
Introduction
Gliomas are brain tumors possessing the characteristics of glial cells, astrocytes, and oligodendrocytes, and have been classified into four grades (WHO grade I-IV) based on their pathological features. Glioblastoma (GBM) is the most malignant glioma (WHO grade IV), and patients with GBM have a median survival of approximately one year. In spite of tremendous efforts to effectively treat GBM, the overall survival rates of patients with GBM have remained unchanged over the past few decades.
The discovery of GBM-initiating cells (GICs) has had a significant impact on GBM research (1) . GICs have a strong self-renewal capability, express stem cell markers, such as CD133 (also known as Prominin1), Sox2, CD15 (also known as Stage-Specific Embryonic Antigen 1 and Lewis X), and CD49f (also known as integrin α 6), and are more resistant to radio-and chemo-therapies higher than nonGICs (2-5). GICs have also been shown to exploit the signaling pathways that are involved in the maintenance of neural stem cells (NSCs) (2) (3) (4) (5) . NSCs exist only in the subventricular zone and hippocampus (6, 7) , both of which contain a special microenvironment (niche) for the maintenance of NSCs, whereas GBM arises in many areas in the brain. It currently remains unknown how GICs maintain their stemness in the brain; whether GICs generate their preferable niche anywhere or employ an unknown mechanism for their maintenance in non-NSC niches.
We previously established the mouse GIC lines (mGICs), NSCL61 and OPCL61, by overexpressing an oncogenic HRas L61 in p53-deficient NSCs and oligodendrocyte precursor cells (OPCs), respectively (8, 9) . These mGICs formed transplantable GBM with hypercellularity, pleomorphism, multinuclear giant cells, mitosis, and necrosis, even when as few as ten cells were injected into the brains of nude mice. These findings indicated that they were highly enriched in bona fide GICs. 4 Using DNA microarray analysis, we compared the gene expression profiles of mGICs with those of their parental cells and identified genes that increased and decreased in mGICs. By evaluating the candidate genes using human GICs (hGICs) and GBM tissues, we have successfully selected potential GIC-specific genes (8) (9) (10) (11) .
Among the candidate genes evaluated, we focused on Epithelial V-like antigen 1 (Eva1, also known as myelin protein Zero-like 2). Eva1 was originally identified as an immunoglobulin superfamily member expressed on the developing thymus epithelial cell membrane and disappeared in the developed one (12) (13) (14) . Eva1 was also shown to be involved in the T cell development through the Eva1-Eva1
homophilic interaction between CD4/CD8 double-positive cells and thymus epithelial cells in the early embryo (12) (13) (14) , however there was no detectable phenotype, including the hematopoietic development, in the Eva1 knockout mice (12-15, Ohtsu et al, unpublished observation). Notably, it has not been shown that Eva1 was involved in either tumorigenesis or stemness. These findings led us to investigate whether Eva1 can be a novel GIC marker and/or a potential therapeutic target.
Here we show the evidence that Eva1 is expressed on GICs and its modulation impacts GIC characteristics, including stemness-related gene expression, side population, self-renewal activity and tumorigenesis, through the non-canonical NF-κB signaling pathway, providing a new molecular mechanism that maintains GIC characteristics.
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Materials and Methods
Animals and Chemicals
Mice were obtained from the Laboratory for Animal Resources and Genetic
Engineering at the RIKEN Center for Developmental Biology (CDB) and from Charles River Japan, Inc. All mouse experimental protocols were approved by the Animal Care and Use Committees of RIKEN CDB, Ehime University, and Hokkaido
University. Chemicals and growth factors were purchased from Sigma-Aldrich and Peprotech, respectively, except where otherwise indicated.
Cell culture
Mouse primary NSCs, NSCL61 cells, human NSCs (hNSCs, Invitrogen) and GICs (hGICs, E2, E3 and E6) were cultured in DMEM/F12 (Gibco, BRL) supplemented with bFGF (10 ng/ml) and EGF (10 ng/ml) (NSC medium), as described previously (8) (9) (10) (11) 16) . For immunostaining, cells were cultured in chamber slides (Nunc) precoated with fibronectin and poly-D-lysine, as described previously (16) .
Immunochemistry
Immunostaining of paraffin-embedded human brain-tumor sections (6 μm thick) and mouse cells or brain sections was performed as described previously (8) . Eva1 was retrieved by HistoVT One according to the supplier's instructions (Nacalai Tesque).
The sections were permeabilized with 0.3% TritonX-100 in PBS for penetration, treated with a blocking solution (2% skim milk, 0.3% Triton X-100, and PBS) for 1 h, and incubated with primary antibodies for 16 h at 4°C. Cells were fixed and immunostained as described previously (16) . The following antibodies were used to detect antigens: rabbit polyclonal anti-Eva1 (10 µg/ml) produced by immunizing a 6 rabbit with a synthetic peptide (CPMSGRFKDRVSWDGNPE) using a standard method ( Fig. S2A and B Alexa568-conjugated goat anti-mouse IgG (Molecular Probe; 1:500), Alexa488-conjugated goat anti-rabbit (Molecular Probe; 1:500), and streptoavidine-Cy3
(Jackson ImmunoResearch; 1:500). Cells were counterstained with DAPI (1 µg/ml) to visualize the nuclei. Fluorescence images were obtained using an AxioImager A1 microscope (Carl Zeiss).
Flow cytometry
Flow cytometry was performed as described previously (11) . The following antibodies were used to detect antigens: rabbit polyclonal anti-Eva1 (5μg/ml), mouse monoclonal anti-CD15 (5μg/ml; BD Pharmingen) and biotinylated mouse The SP was analyzed as shown previously (15) . Reserpine (10 μM), an inhibitor of some ABC transporters, was used to identify SP.
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Human brain tumors
Human GICs were used according to the research guidelines of the Ehime University Mouse brains were dissected, fixed in 4% paraformaldehyde at 4°C overnight, transferred to 70% ethanol, processed on Tissue-Tek VIP (Sakura Finetek Japan, Tokyo, Japan), and embedded in paraffin. Coronal sections (6-μm thick) from the cerebral cortex were prepared on a microtome and stained with hematoxylin-eosin (HE).
RT-PCR
RT-PCR was performed as described previously (16) for eva1, as follows: 5' primer, 5'-TTCTCCAGCTTTGCCCCTGT-3'; 3' primer, 5'-CCGCCCATCGCTTTTTCCGG-3'. The primers for gapdh were as described previously (14) .
Vector construction
Complementary DNAs (cDNAs) were cloned as described previously (8) . Human To knockdown mouse and human eva1 and mouse relb, short-hairpin (sh) sequences were generated using InvivoGen's siRNA Wizard (http://www.sirnawizard.com/). We used the mouse rela sh sequence described previously (17) . These sh sequences were inserted into a psiRNA-h7SKhygro G1 expression vector (InvivoGen) to produce psiRNA-h7SKhygro-meva1sh, psiRNAh7SKhygro-heva1sh1, psiRNA-h7SKhygro-heva1sh2, psiRNA-h7SK-relash (relash), and psiRNA-h7SK-relbsh (relbsh). The knockdown efficiency of these vectors was We transfected the cells with the vectors using either the Nucleofector device according to the supplier's instructions (Lonza) or Polyethylenimine (PEI), as previously described (7, 18) .
Cytotoxicity assay
To examine the function of the NF-κB signaling pathway in GICs, mouse and human GICs were cultured in various concentrations of CAPE (Calbiochem), pterostilbene (Tokyo Chemical Industry Co., LTD.) or DMSO alone (control) for 3 days and assayed for viability by the MTT assay as described previously (8) .
Gene microarray and pathway analyses
A 3D-Gene Mouse Oligo chip 24k (23,522 distinct genes, Toray) was used in the DNA microarray analysis. Total RNA was labeled with Cy5 using the Amino Allyl http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72849.
Immunoprecipitation and Western blotting
Immunoprecipitation was performed as previously described (19) . Cell lysates were incubated with Protein G sepharose (GE Healthcare) and the anti-Eva1 (2 μg/ml) 11 antibody for 4 h at 4°C. The mixtures were centrifuged, and the precipitants were triple-washed and analyzed by Western blotting.
Western blotting was performed as previously described (19) . The blotted membranes were probed with an anti-Eva1 (2 μg/ml), rabbit anti-NF-κB2 (Cell Signaling Technology, 1:500), mouse anti-cIAP (R&D Systems, 1:500), rabbit anti-TRAF2 (Cell Signaling Technology, 1:500), rabbit anti-NIK (Cell Signaling Technology, 1:500), anti-RelA (SIGMA, 1:500), anti-RalB (Cell Signaling Technology, 1:500), or mouse anti-GAPDH antibody (Chemicon, 1:1000). An ECL system (Amersham) was used for detection.
Luciferase assay
Luciferase was assayed as described previously (19) . Using PEI, NSCL61 cells were (Promega), which encoded sea pansy luciferase. After two days, the activities of the two types of luciferases were measured using the Dual-Luciferase Reporter Assay System according to the supplier's instructions (Promega).
TCGA analysis
Relationship between eva1 expression and the prognosis of GBM patients, % survival and % disease free, was analyzed by using the cBioPortal (20, 21 
Results
Eva1 was identified as a novel GIC marker
We first examined the expression of eva1 in mGICs, NSCL61 and OPCL61, and hGICs, E2, E3 and E6 that were prepared from human GBM tissues (8,10), using RT-PCR. As shown in Figure 1A , eva1 expression was higher in GICs than in their control cells, mNSC, mOPC and normal hNSC. We confirmed the increased Eva1 expression in human and mouse GICs by western blotting (Fig. 1B) and qRT-PCR (Fig. 1B, S1A and S1B). Immunocytochemical analysis revealed that over 90% of cultured human and mouse GICs were positive for Eva1 ( Fig. 1C and S2C , respectively). These Eva1-positive cells existed in human GBM and were coimmunolabeled for a well-known NSC marker Sox2 (>80%, Fig. 1D ), a GIC marker CD15 (Fig. 1E) and CD49f ( Fig. 1F ) (22) (23) (24) . Flow cytometric analysis showed that 2.1% of the freshly prepared GBM cells were Eva1+ and that about 70% and 50% of Eva1+ cells were also positive for CD15 and CD49f, respectively ( Fig. 1G and H) .
We further found that Eva1 was undetectable in the adult mouse brain (P100),
although it was restrictedly expressed in developing mouse neuroepithelial cells (at E18 and P1) that included multipotent NSCs (25) (26) (27) (Fig. S2D) . Taken together, these results indicated that Eva1 is a potential GIC marker.
Eva1 was prominently expressed in GBM, but not in other gliomas, such as anaplastic oligodendroglioma (AO, WHO grade III), anaplastic oligoastrocytoma (AOA, WHO grade III), or oligodendroglioma (OLI, WHO grade II) ( Fig. 2A and B) .
The cBioPortal Data
(http://www.cbioportal.org/index.do?cancer_study_list=&cancer_study_id=all&data_ priority=0&case_ids=&gene_set_choice=user-definedlist&gene_list=&clinical_param_selection=null&tab_index=tab_visualize) (22, 21) suggested that the prognosis of GBM patients with elevated eva1 mRNA levels (black dashed line, Z-score>2) was worse than the other (gray solid line); median survival and median disease free of the patients (dashed black line) with elevated eva1 was 10.41 and 2.89 months (M), whereas those of the other (solid gray line) was 12.98 and 7 M, respectively (Fig. 2C) . The Cancer Genome Atlas (TCGA) analysis (http://cancergenome.nih.gov) further revealed that expression of eva1 significantly increased in GBM compared with the lower grade glioma (LGG), whereas that of CD15, Sox2 or CD49f did not (Fig. 2D) . These results suggested that Eva1 is a new prognostic marker for GBM.
Eva1 was involved in the GIC proliferation and tumorigenesis
We analyzed the function of Eva1 in GICs using eva1 and its specific shRNA (sh1 and sh2) expression vectors (Fig. S3) . Overexpression of eva1 increased the expression of stemness genes, sox2, cd15 and cd49f, and the self-renewal activity in GICs, whereas its knockdown blocked these activation (Fig. 3A-C, S4A and S4B).
hGICs formed malignant tumor with hypercellularity and mitosis when injected into the brains of immunodeficient mice, whereas the eva1sh-expressing cells did not and the mice injected with the eva1sh-expressing GICs survived over 3 months (Fig. 3C, data not shown). In addition, enforced expression of eva1 increased self-renewal activity in hGICs (Fig. S4B ) and enhanced tumorigenicity of two primary human gliomasphere lines established from AO ( Fig. 3D and E) and diffuse astrocytoma (DA, WHO grade II, Fig. 3F and G) , both of which were Eva1-negative. These Eva1-overexpressing AO and DA cells killed mice more quickly (30 and 55 days, respectively, n=6) than their parental cells (over 60 and 90 days, respectively, to form tumors, n=6) ( Fig. 3E and G, respectively) when inoculated into the immunodeficient 15 mice intracranially. Together, these results clearly indicated that Eva1 is involved in the GIC proliferation and tumorigenesis.
Eva1 increased the expression of stemness-related genes and the side population through the NF-κB activation in GICs
In order to identify the molecular mechanism that regulated by Eva1, we compared the gene expression profile of NSCL61 with that of eva1sh-expressing NSCL61. We found that 1,208 genes were upregulated while 650 were downregulated in eva1sh-expressing NSCL61 (Fig. S5A ). We noted a significant down-regulation in the expression of stemness-related genes, including aldehyde dehydrogenase 1a3
(aldh1a3), Hairy/enhancer-of-split related with YRPW motif protein 1 (hey1), notch 4, jagged 1 (jag1), cytokine receptor 4 (cxcr4), pr domain containing 16 (prdm16) and syndecan 1 (sdc1). The expression of the ATP-Binding Cassette (ABC) transporter
G2 (abcg2) also decreased in the eva1sh-expressing NSCL61 (Log2 ratio: -0.6).
Using RT-PCR, we confirmed the decreased expression level of stemness-related genes, aldh1a3, hey1, prdm16, notch4 and abcg2 in eva1sh-expressing NSCL61 (Fig.   S5B ). These results suggested that Eva1 widely regulates the stemness-related gene expression in GICs. Indeed, overexpression of Eva1 increased the SP in hGICs (E3:
21% -> 41%, E6: 22% -> 43%), whereas that of eva1sh abolished the population (E3:
22% -> 0.3% (sh1) and 1.9% (sh2), E6: 24% -> 0.3% (sh1) and 1.2% (sh2)) ( Fig. 4A and B). Eva1 level also affected Nestin expression in hGICs and its knockdown significantly increased the differentiation marker-positive cells (Fig. 4C-F) .
Apparently, these data indicated that Eva1 is involved in the stemness maintenance in
GICs.
Network Analysis software in MetaCore TM (GeneGO) revealed that the knockdown of Eva1 in NSCL61 influenced the expression of a number of oncogenic transcription networks, including p53, Hypoxia-inducing factor 1α (HIF1α), c-Myc, Nuclear factor-kappa B (NF-κB), and STAT3 (Fig. S5C ). Of these, we focused on To evaluate whether Eva1 activates the NF-κB signaling pathway, we inserted four copies of a NF-κB response element into a reporter vector that contained a minimal SV40 promoter upstream of the firefly luciferase gene. We also constructed two other reporter vectors that contain four copies of a response element for AP1 and SP1 transcription factors, both of which were affected the most in eva1sh-expressing NSCL61. We transfected these vectors into NSCL61 and found the increased luciferase activity when transfected with the NF-κB-reporter vector (white columns in Fig. S6A ). We also detected the NF-κB-dependent luciferase activity in hGICs (white columns in Fig. 5A ). Using eva1sh-and eva1-overexpressing hGICs and NSCL61, we found that NF-κB-dependent luciferase activity correlated with Eva1 levels (Fig. 5A and B and Fig. S6A and B) . To further verify the role of NF-κB signaling in GICs, we used two NF-κB inhibitors, caffeic acid phenethyl ester (CAPE) and pterostilbene (29, 30) . These inhibitors dramatically blocked the proliferation of both hGIC and NSCL61 in a dose-dependent manner (Fig. 5C and D and Fig. S6C ). In addition,
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CAPE also inhibited the proliferation of Eva1-overexpressing DA cells, while it partially repressed the proliferation of parental cells (Fig. 5E ). Taken together, these findings revealed that the Eva1 plays a role in the stemness maintenance of GICs and their proliferation through the activation of NF-κB signaling pathway.
The non-canonical NF-κB signaling pathway is essential for GIC proliferation and tumorigenesis
The receptor-mediated activation of NF-κB has been shown to induce the expression of many genes that regulate inflammation, cell proliferation, immune responses, and tumorigenesis through either canonical or non-canonical signaling pathways (31, 32) .
RelA/p50NF-κB1 and RelB/p52NF-κB2 complexes have been identified as key components in the canonical and non-canonical NF-κB signaling pathways, respectively, while the receptor-binding protein TRAF2 was shown to regulate both pathways (28, 31, 32) . We addressed which of these pathways was crucial for GICs.
Using rela-and relb-shRNA expression vectors (relash and relbsh, respectively) ( Fig.   S7A ), we found that the depletion of RelB, but not RelA, inhibited the NF-κB-dependent luciferase activity in hGICs and NSCL61 ( Fig. 6A and Fig. S7B , respectively). The knockdown of RelB also blocked the proliferation of E3, NSCL61
and Eva1-overexpressing DA cells and the self-renewal activity of hGICs (Fig. 6C,   S7C and S4C, respectively, data not shown for Eva1-expressing DA cells). In addition,
RelB knockdown completely abolished tumorigenesis of NSCL61 in vivo (Fig. S7D) .
We further found the increased levels of RelB, NIK, a key non-canonical NF-κB-inducing kinase (28, 31, 32) , and the mature form (p52) of NF-κB2 (immature form: p100) in primary human GBM tissues (Fig. 6D) . Furthermore, prognosis of GBM patients with elevated relB mRNA levels (red line) was worse than the others (blue 18 line) (Fig. S8A, Z-score>2 ) and the expression of relB significantly increased in GBM compared with in LGG (Fig. S8B) . Together, these data indicated that RelB is essential for GIC proliferation and tumorigenesis.
Eva1 activated the non-canonical NF-κB signaling pathway through NIK stabilization and NF-κB2 maturation in GICs
To confirm whether Eva1 activates the RelB-dependent non-canonical NF-κB pathway, we used the Eva1-overexpressing DA cells. As shown in Figure 6E , Eva1-overexpression significantly increased the level of RelB, NIK and the mature form of NF-κB2 (p52) in DA cells. A previous study reported that NIK was destabilized by a complex with TRAF2, TRAF3 and the cellular inhibitor of apoptosis (cIAP), while TRAF2 and cIAP were degraded by the proteasome in the receptor-mediated NF-κB-activation pathway (33) . Together with that Eva1 cytoplasmic tail contains a putative TRAF2 binding site, these suggest that Eva1 sequesters the TRAF2 and cIAPcontaining complex and induces its degradation, thereby resulting in the accumulation of NIK in GICs. To examine this possibility, we cultured Eva1-overexpressing DA cells in the presence or absence of a proteasome inhibitor (PI) and found that both TRAF2 and cIAP were co-immunoprecipitated with Eva1 only in the presence of PI (Fig. 6F) . These results indicated that Eva1 directly activates the non-canonical NF-κB signaling pathway through the TRAF2/cIAP degradation-dependent NIK accumulation in GICs (Fig. 6G) .
Discussion
Eva1 was originally identified as an immunoglobulin superfamily member expressed on the developing thymus epithelial cells and was shown to be involved in the T cell development in the early embryo (12, 13) . Aberrant canonical and non-canonical NF-κB signalings were previously reported in various types of solid tumors including GBM (48) (49) (50) . NF-κB activation has been further shown to make GICs be resistant to irradiation through the acquirement of mesenchymal phenotypes (50) . We found that E3 is the proneural type of GIC, which strongly express olig2, dll3 and ascl1, whereas E6 is the mesenchymal type one, which prominently express serpine1, chi3l1 (also known as ykl40), vegfc and runx1, although non-canonical NF-κB signaling was activated in both GICs.
Together, these findings suggested that non-canonical NF-κB signaling could not induce mesenchymal phenotypes in GICs (10, data not shown). Nonetheless, since the 
